A new Surescripts survey shows that 94% of respondents who skipped taking a medication because it cost too much would have been willing to take a lower-cost alternative if that were suggested.
Chester "Chip" Davis' is leaving AAM, to serve as HDA president and CEO; Jeffrey Francer, AAM's senior vice president and general counsel, will serve as interim AAM CEO.